UroGen Pharma (URGN) Operating Leases (2019 - 2026)

UroGen Pharma (URGN) has reported Operating Leases for 8 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.

• Quarterly Operating Leases rose 98.77% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (up 98.77% YoY) and the FY2025 annual result came in at $6.1 million, up 270.36% from the prior year.
• Operating Leases fell to $5.6 million in Q1 2026 per URGN's latest filing, from $6.1 million in the prior quarter.
• Over the last five years, Operating Leases for URGN reached as high as $6.2 million in Q3 2025 and fell as low as $844000.0 in Q4 2023.
• A 5-year average of $2.7 million and a median of $2.3 million in 2022 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases surged 534.92% — and 2023, when it plunged 66.6%.
• Year by year, Operating Leases stood at $2.5 million in 2022, then tumbled by 66.6% to $844000.0 in 2023, then soared by 95.85% to $1.7 million in 2024, then jumped by 270.36% to $6.1 million in 2025, then dropped by 7.76% to $5.6 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $5.6 million, $6.1 million, and $6.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.